Catalog No.
RHG49401
Species reactivity
Human
Host species
Mouse
Isotype
IgG1
Clonality
Monoclonal
Tested applications
ELISA: 1:10000, FCM: 1:200-1:400
Target
Leukointegrin alpha D, Integrin alpha-D, CD11d, CD11 antigen-like family member D, ITGAD, ADB2
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q13349
Applications
ELISA, FCM
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.05% Sodium Azide.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
R3S37
Humanized anti-CD11d monoclonal antibodies suitable for basic research and therapeutic applications., PMID:39839909
CD11d is a novel antigen on chicken leukocytes., PMID:32534212
Characterisation of a New Human Alveolar Macrophage-Like Cell Line (Daisy)., PMID:31732808
The effectiveness of the anti-CD11d treatment is reduced in rat models of spinal cord injury that produce significant levels of intraspinal hemorrhage., PMID:28587875
The Role of Integrins αMβ2 (Mac-1, CD11b/CD18) and αDβ2 (CD11d/CD18) in Macrophage Fusion., PMID:27315778
CD11d integrin blockade reduces the systemic inflammatory response syndrome after traumatic brain injury in rats., PMID:26169930
Immunohistochemical evaluation of the effects of paraffin section storage on biomarker stability., PMID:23435571
Treatment with an anti-CD11d integrin antibody reduces neuroinflammation and improves outcome in a rat model of repeated concussion., PMID:23414334
Hepatosplenic and hepatocytotropic T-cell lymphoma: two distinct types of T-cell lymphoma in dogs., PMID:22711745
A CD11d monoclonal antibody treatment reduces tissue injury and improves neurological outcome after fluid percussion brain injury in rats., PMID:22676851
The systemic inflammatory response after spinal cord injury in the rat is decreased by α4β1 integrin blockade., PMID:22150233
Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury., PMID:22078757
CD11d Antibody Treatment Improves Recovery in Spinal Cord-Injured Mice., PMID:22044160
Characterization of immune cell infiltration into canine intracranial meningiomas., PMID:21987303
CD11d integrin blockade reduces the systemic inflammatory response syndrome after spinal cord injury., PMID:21784069
Anti-CD11d monoclonal antibody treatment for rat spinal cord compression injury., PMID:21145887
A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury., PMID:20146558
A systematic review of directly applied biologic therapies for acute spinal cord injury., PMID:20082560
Mary Allen Engle Award: The glue of life--a career retrospective., PMID:21686217
Gene expression profiling in anti-CD11d mAb-treated spinal cord-injured rats., PMID:19250688
The role of integrin alpha D beta2 (CD11d/CD18) in monocyte/macrophage migration., PMID:18621369
Transient blockage of the CD11d/CD18 integrin reduces contusion volume and macrophage infiltration after traumatic brain injury in rats., PMID:18374312
Comparison of two polymer-based immunohistochemical detection systems: ENVISION+ and ImmPRESS., PMID:17204059
An established feline monocytic cell line., PMID:17058791
A therapeutic time window for anti-CD 11d monoclonal antibody treatment yielding reduced secondary tissue damage and enhanced behavioral recovery following severe spinal cord injury., PMID:17048772
Methylprednisolone causes minimal improvement after spinal cord injury in rats, contrasting with benefits of an anti-integrin treatment., PMID:16379576
Autonomic dysreflexia after spinal cord injury: central mechanisms and strategies for prevention., PMID:16198705
Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats., PMID:15992367
Comparison of effects of methylprednisolone and anti-CD11d antibody treatments on autonomic dysreflexia after spinal cord injury., PMID:15890340
Anti-CD11d integrin antibody treatment restores normal serotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord., PMID:15659600
A monoclonal antibody to CD11d reduces the inflammatory infiltrate into the injured spinal cord: a potential neuroprotective treatment., PMID:15465595
An anti-CD11d integrin antibody reduces cyclooxygenase-2 expression and protein and DNA oxidation after spinal cord injury in rats., PMID:15312174
Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function., PMID:15102919
Early anti-inflammatory treatment reduces lipid peroxidation and protein nitration after spinal cord injury in rats., PMID:15009633
Inhibition of monocyte/macrophage migration to a spinal cord injury site by an antibody to the integrin alphaD: a potential new anti-inflammatory treatment., PMID:11031083
Neutrophil transmigration across human airway epithelial monolayers: mechanisms and dependence on electrical resistance., PMID:10970831
Characterization of the diffuse mucosal associated lymphoid tissue of feline small intestine., PMID:10889297
The leukocyte integrin alpha D beta 2 binds VCAM-1: evidence for a binding interface between I domain and VCAM-1., PMID:10438935
alphadbeta2 integrin is expressed on human eosinophils and functions as an alternative ligand for vascular cell adhesion molecule 1 (VCAM-1)., PMID:9841932
The leukointegrin alpha d/beta 2 (alpha d/CD18): specific changes in surface expression in patients on hemodialysis., PMID:9759518
Requirements for alpha d in IgG immune complex-induced rat lung injury., PMID:9551942
For research use only. Not for human or drug use.
